Skip to main content
NCBI home page
The Iowa Orthopaedic Journal logoLink to The Iowa Orthopaedic Journal
. 1996;16:39–45.

Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions.

L J Weinstein 1, E F McCarthy 1
PMCID: PMC2378124  PMID: 9129273

Full text

PDF
39

Images in this article

39Figure 1
on p.39
39Figure 2
on p.39
42Figure 3
on p.42
42Figure 4
on p.42
42Figure 5
on p.42
44Figure 6A
on p.44
44Figure 6B
on p.44
44Figure 6C
on p.44
44Figure 6D
on p.44

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alho A., Connor J. F., Mankin H. J., Schiller A. L., Campbell C. J. Assessment of malignancy of cartilage tumors using flow cytometry. A preliminary report. J Bone Joint Surg Am. 1983 Jul;65(6):779–785. [PubMed] [Google Scholar]
  2. Brown D. C., Gatter K. C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990 Dec;17(6):489–503. doi: 10.1111/j.1365-2559.1990.tb00788.x. [DOI] [PubMed] [Google Scholar]
  3. Burger P. C., Shibata T., Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol. 1986 Sep;10(9):611–617. doi: 10.1097/00000478-198609000-00003. [DOI] [PubMed] [Google Scholar]
  4. Evans H. L., Ayala A. G., Romsdahl M. M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977 Aug;40(2):818–831. doi: 10.1002/1097-0142(197708)40:2<818::aid-cncr2820400234>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  5. Hasegawa T., Seki K., Yang P., Hirose T., Hizawa K., Wada T., Wakabayashi J. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone. Hum Pathol. 1995 Aug;26(8):838–845. doi: 10.1016/0046-8177(95)90004-7. [DOI] [PubMed] [Google Scholar]
  6. Kreicbergs A., Boquist L., Borssén B., Larsson S. E. Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features. Cancer. 1982 Aug 1;50(3):577–583. doi: 10.1002/1097-0142(19820801)50:3<577::aid-cncr2820500332>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  7. Lichtenstein L., Jaffe H. L. Chondrosarcoma of Bone. Am J Pathol. 1943 Jul;19(4):553–589. [PMC free article] [PubMed] [Google Scholar]
  8. Mirra J. M., Gold R., Downs J., Eckardt J. J. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res. 1985 Dec;(201):214–237. [PubMed] [Google Scholar]
  9. Montine T. J., Vandersteenhoven J. J., Aguzzi A., Boyko O. B., Dodge R. K., Kerns B. J., Burger P. C. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery. 1994 Apr;34(4):674–679. doi: 10.1227/00006123-199404000-00016. [DOI] [PubMed] [Google Scholar]
  10. Nielsen A. L., Nyholm H. C. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumours from patients with and without previous oestrogen therapy. J Pathol. 1993 Nov;171(3):199–205. doi: 10.1002/path.1711710308. [DOI] [PubMed] [Google Scholar]
  11. Pritchard D. J., Lunke R. J., Taylor W. F., Dahlin D. C., Medley B. E. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer. 1980 Jan 1;45(1):149–157. doi: 10.1002/1097-0142(19800101)45:1<149::aid-cncr2820450125>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  12. Rosenthal D. I., Schiller A. L., Mankin H. J. Chondrosarcoma: correlation of radiological and histological grade. Radiology. 1984 Jan;150(1):21–26. doi: 10.1148/radiology.150.1.6689763. [DOI] [PubMed] [Google Scholar]
  13. Sanerkin N. G. The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach. Cancer. 1980 Feb;45(3):582–594. doi: 10.1002/1097-0142(19800201)45:3<582::aid-cncr2820450326>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  14. Schiller A. L. Diagnosis of borderline cartilage lesions of bone. Semin Diagn Pathol. 1985 Feb;2(1):42–62. [PubMed] [Google Scholar]
  15. Schröder R., Bien K., Kott R., Meyers I., Vössing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol. 1991;82(5):389–394. doi: 10.1007/BF00296550. [DOI] [PubMed] [Google Scholar]
  16. Scotlandi K., Serra M., Manara M. C., Maurici D., Benini S., Nini G., Campanacci M., Baldini N. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 1995 Feb 1;75(3):806–814. doi: 10.1002/1097-0142(19950201)75:3<806::aid-cncr2820750310>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  17. Shepherd N. A., Richman P. I., England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol. 1988 Jul;155(3):213–219. doi: 10.1002/path.1711550306. [DOI] [PubMed] [Google Scholar]
  18. Vollmer E., Roessner A., Wuisman P., Härle A., Grundmann E. The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67. Curr Top Pathol. 1989;80:91–114. doi: 10.1007/978-3-642-74462-4_4. [DOI] [PubMed] [Google Scholar]
  19. Wintzer H. O., Zipfel I., Schulte-Mönting J., Hellerich U., von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 Jan 15;67(2):421–428. doi: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  20. Yu C. C., Filipe M. I. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem J. 1993 Dec;25(12):843–853. [PubMed] [Google Scholar]

Articles from The Iowa Orthopaedic Journal are provided here courtesy of The University of Iowa

RESOURCES